Relmada Therapeutics, Inc. SEC filings RLMD
Relmada Therapeutics, Inc. has 606 filings in SEC EDGAR's recent list, going back to Nov 13, 2012. Its latest annual report, Form 10-K, was filed on Mar 19, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 8, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Apr 9, 2026 | — |
| CORRESP | Letter to the SEC | Apr 7, 2026 | — |
| UPLOAD | Letter from the SEC | Apr 7, 2026 | — |
| EFFECT | Filing | Sep 12, 2024 | — |
| CORRESP | Letter to the SEC | Sep 11, 2024 | — |
| UPLOAD | Letter from the SEC | Sep 6, 2024 | — |
| EFFECT | Filing | Aug 21, 2020 | — |
| CORRESP | Letter to the SEC | Aug 19, 2020 | — |
| UPLOAD | Letter from the SEC | Aug 18, 2020 | — |
| EFFECT | Filing | Oct 31, 2019 | — |
| EFFECT | Filing | Oct 31, 2019 | — |
| CORRESP | Letter to the SEC | Oct 30, 2019 | — |
| CORRESP | Letter to the SEC | Oct 28, 2019 | — |
| UPLOAD | Letter from the SEC | Oct 25, 2019 | — |
| EFFECT | Filing | Oct 23, 2019 | — |
| CORRESP | Letter to the SEC | Oct 21, 2019 | — |
| CORRESP | Letter to the SEC | Oct 17, 2019 | — |
| UPLOAD | Letter from the SEC | Oct 16, 2019 | — |
| CORRESP | Letter to the SEC | Oct 11, 2019 | — |
| D | Filing | Oct 8, 2019 | — |
| CERT | Filing | Oct 8, 2019 | — |
| 8-A12B | Form 8-a12b | Oct 8, 2019 | — |
| SEC STAFF ACTION | Filing | Sep 23, 2019 | — |
| UPLOAD | Letter from the SEC | Aug 20, 2019 | — |
| D/A | Filing | Jul 10, 2019 | — |
| D | Filing | Jun 27, 2019 | — |
| D | Filing | May 16, 2019 | — |
| EFFECT | Filing | Mar 1, 2019 | — |
| CORRESP | Letter to the SEC | Feb 28, 2019 | — |
| UPLOAD | Letter from the SEC | Feb 8, 2019 | — |
| D/A | Filing | Dec 10, 2018 | — |
| D/A | Filing | Nov 13, 2018 | — |
| D | Filing | Oct 22, 2018 | — |
| D | Filing | Oct 6, 2017 | — |
| DFAN14A | Filing | Dec 9, 2015 | — |
| DFAN14A | Filing | Dec 7, 2015 | — |
| 8-A12G | Registration of certain classes of securities | Jan 6, 2015 | — |
| EFFECT | Filing | Dec 30, 2014 | — |
| CORRESP | Letter to the SEC | Dec 23, 2014 | — |
| CORRESP | Letter to the SEC | Dec 9, 2014 | — |
| UPLOAD | Letter from the SEC | Dec 3, 2014 | — |
| CORRESP | Letter to the SEC | Nov 17, 2014 | — |
| UPLOAD | Letter from the SEC | Nov 3, 2014 | — |
| CORRESP | Letter to the SEC | Oct 16, 2014 | — |
| UPLOAD | Letter from the SEC | Oct 1, 2014 | — |
| CORRESP | Letter to the SEC | Sep 16, 2014 | — |
| UPLOAD | Letter from the SEC | Jul 24, 2014 | — |
| D | Filing | Jun 19, 2014 | — |
| D | Filing | Jun 4, 2014 | — |
| NT 10-Q | Mainbody | Apr 14, 2014 | Feb 28, 2014 |
| NT 10-K | Mainbody | Nov 26, 2013 | Aug 31, 2013 |
| EFFECT | Filing | Mar 22, 2013 | — |
| CORRESP | Letter to the SEC | Mar 19, 2013 | — |
| UPLOAD | Letter from the SEC | Mar 1, 2013 | — |
| UPLOAD | Letter from the SEC | Feb 8, 2013 | — |
| UPLOAD | Letter from the SEC | Dec 10, 2012 | — |
Showing 56 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RLMD (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Coral Gables, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1553643
- Former names
- CAMP NINE, INC. (until Jul 14, 2014)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.